Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

Shares of Novo Nordisk (NVO) gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill, amycretin, at the European Association for the Study of Diabetes meeting in Madrid.NVO’s Amycretin Shows Efficacy Superior to Wegovy in StudyNovo Nordisk’s oral obesity pill, amycretin, showed faster weight loss than its blockbuster weekly injection for chronic weight management, Wegovy (semaglutide), in the phase I stud ...